Get all your news in one place.
100’s of premium titles.
One app.
Start reading
The Street
The Street
Business
Ian Krietzberg

Cathie Wood snaps up $5 million of tech stock PacBio

Shares of Pacific Biosciences of California (PACB) -), a life science technology company focused on solving genetic problems, are struggling lately. After climbing to 52-week highs in July, the company's stock plummeted throughout August, then again in the second half of September. 

Up around 10% for the year, PacBio shares began to climb at the beginning of October, making up some lost ground. 

Related: Cathie Wood buys into recently declining tech stock for millions of dollars

On Oct. 11, PacBio made available a new, standardized computational method for genome sequencing data analysis. This latest release streamlines genome sequencing into a single workflow, integrating a number of third-party tools and granting customers access to a high-performance solution, according to a company statement.

In the midst of this ongoing volatility, Cathie Wood, the CEO and investment lead of Ark Invest, boosted her firm's holding in PacBio by more than $5 million Oct. 11. Ark's flagship Innovation ETF, at 588,818 shares, picked up the bulk of the purchase. Ark Innovation now holds a total of 17.2 million shares in PacBio, worth $155 million and weighted at 2.23% of the fund. 

The biotech firm's second quarter of 2023 saw a 34% increase in revenue to $47.6 million, compared to the $35.5 million it earned in the year-ago period. PacBio's operating expenses for the quarter, however, increased to $88.7 million, above the $84.2 million the company noted in operating expenses the previous year. 

More on Ark Invest:

PacBio reported a net loss for the quarter of $69.8 million, slightly better than the $71.4 million it lost last year. 

The average analyst price target for the tech firm is pegged at $13.10, with a consensus rating of a moderate buy. Barclays cut its price target for PacBio at the end of September, from $14 to $9. 

Shares of PacBio rose slightly in pre-market trading to $9.09. 

Ark Innovation additionally sold 37,268 shares of Tesla (TSLA) -), trimming the firm's most bullish holding by nearly $10 million. 

Action Alerts PLUS offers expert portfolio guidance to help you make informed investing decisions. Sign up now.

Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.